Tag Archives: sporadic inclusion body myositis

US FDA granted breakthrough therapy designation to Novartis’s BYM338 for sporadic inclusion body myositis

Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the potential to be the first treatment for sIBM patients BYM338 is the third Novartis investigational treatment this year to receive … Read the full press release